Stoppel Laura
SEC insider (Form 3/4/5 filer). CIK 0001865119. Director at Artiva Biotherapeutics, Inc. (ARTV) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Sep 10, 2026. Located in SAN DIEGO, CA.
Companies Stoppel Laura has filed insider reports for
- Artiva Biotherapeutics, Inc. (ARTV): Director
- Acumen Pharmaceuticals, Inc. (ABOS): Director
Stoppel Laura
CIK: 0001865119
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Sep 10, 2026ARTV
Artiva Biotherapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
16.3K shares- - Sep 8, 2026ARTV
Artiva Biotherapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
13.8K shares- - Jun 3, 2026ABOS
Acumen Pharmaceuticals, Inc.
AwardDirect35.5K shares- - Jun 24, 2025ARTV
Artiva Biotherapeutics, Inc.
AwardDirectDirector Stock Option (Right to Buy)
13.8K shares- - Jun 4, 2025ABOS
Acumen Pharmaceuticals, Inc.
AwardDirect12.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 |  ARTV Artiva Biotherapeutics, Inc. | Award Director Stock Option (Right to Buy) | 16,250 | - | - | Direct |
| Sep 8, 2026 | ARTV Artiva Biotherapeutics, Inc. | Award Director Stock Option (Right to Buy) | 13,750 | - | - | Direct |
| Jun 3, 2026 |  ABOS Acumen Pharmaceuticals, Inc. | Award | 35,500 | - | $0 | Direct |
| Jun 24, 2025 | ARTV Artiva Biotherapeutics, Inc. | Award Director Stock Option (Right to Buy) | 13,750 | - | - | Direct |
| Jun 4, 2025 | ABOS Acumen Pharmaceuticals, Inc. | Award | 12,800 | - | - | Direct |
1-5 of 5 transactions